V
VLP Therapeutics
Developing innovative medical treatments to transform traditional vaccine and targeted antibody therapies
About VLP Therapeutics
VLP Therapeutics is a biotechnology company developing next-generation therapeutic and prophylactic vaccines targeting cancer and infectious diseases, including malaria, dengue, and COVID-19. The company was founded in 2012 in Gaithersburg, Maryland, by Dr. Wataru Akahata, Dr. Ryuji Ueno, and Dr. Sachiko Kuno to translate innovative virus-like particle (VLP) vaccine technologies into clinical therapies.
The company originated from the work of Dr. Wataru Akahata, a virologist who conducted vaccine research at Kyoto University and later spent a decade at the U.S. National Institutes of Health (NIH) Vaccine Research Center. During his time at NIH, Akahata developed a virus-like particle vaccine for the Chikungunya virus, which received the NIH Director’s Award in 2012 and demonstrated the potential of VLP-based immunization approaches. Encouraged by co-founders Ueno and Kuno, Akahata established VLP Therapeutics to advance these technologies toward commercial vaccines.
VLP Therapeutics develops vaccines using two proprietary technology platforms: the inserted alphavirus virus-like particle (i-αVLP) platform and a self-amplifying RNA (replicon) platform. The i-αVLP platform uses virus-like particles that mimic the structure of viruses to trigger strong immune responses without containing genetic material, making them incapable of replication or infection, and is being applied to vaccines for cancer, malaria, and dengue. The replicon platform enables vaccine RNA to self-amplify within cells, allowing effective immune responses with smaller doses than conventional mRNA vaccines and supporting scalable manufacturing. The company’s pipeline includes a malaria vaccine candidate (VLPM-01) that has completed Phase 1 clinical trials, as well as vaccine programs for dengue, cancer immunotherapy, and COVID-19 in various stages of development.
To support its research and development activities, VLP Therapeutics has raised venture funding including a $16 million Series A round (March 2021) and a $21 million Series A-1 round (December 2021). Investors include Sojitz Corporation, MIYAKO Capital, Nobelpharma, and MUFG Bank.
The company operates internationally, with a subsidiary in Japan responsible for advancing RNA vaccine development and manufacturing capabilities.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Nov 2025 | $105K | — | Vinnova | ↗ |
| GRANT✓Other financing | Nov 2025 | $2.8M | — | Bill & Melinda Gates Foundation | ↗ |
Growth signals
Latest recorded traffic for VLP Therapeutics is 1.9K monthly website visits, up 18.8% over the last three months. VLP Therapeutics's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Metri BioTherapeutics for endometrial diseases using 3D modeling |
Boston, United States | Operational | 8 | $5M | $20M |
AfyniaEndometriosis tests |
Hamilton, Canada | Operational | |||
Swan NeuroTechDeveloping biodegradable implants that deliver drugs to promote nerve regeneration after injury. |
Pittsburgh, United States | Operational | |||
Orna TherapeuticsOrna Therapeutics - Ahead of the Curve |
Cambridge, United States | Acquired | |||
Acorn BiolabsAcorn Biolabs - Accessible and Affordable Stem Cell Collection |
Toronto, Canada | Operational | |||
PinCellDeveloping new treatments for different dermatological diseases, particularly orphan diseases of the skin |
Milan, Italy | Acquired | |||
Korro BioEfficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms |
Cambridge, United States | Acquired | |||
Aelis FarmaBiotech company conducting research and development on innovative signaling specific drugs |
Bordeaux, France | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
VLP Therapeutics in the Rockville ecosystem
The VLP Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Global Health Innovative Technology Fund
Vinnova
Bill & Melinda Gates Foundation
Series A8 investors entered at this stage
Miyako Capital
Sojitz- RFRJ Fund
Robert Hisaoka- KCKonishiyasu Co
- SFSK Impact Fund
MUFG Bank- NONobelpharma
Other known investors4 additional known investors
Kyoto University
BioHealth Innovation
Maryland Industrial Partnerships
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about VLP Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VLP Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










